• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chapter 2: Use of iron to treat anemia in CKD.

出版信息

Kidney Int Suppl (2011). 2012 Aug;2(4):292-298. doi: 10.1038/kisup.2012.34.

DOI:10.1038/kisup.2012.34
PMID:25018949
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4089602/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e75/4089602/8963b6a95fe0/kisup201234f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e75/4089602/cd5f7ee02ada/kisup201234f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e75/4089602/8963b6a95fe0/kisup201234f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e75/4089602/cd5f7ee02ada/kisup201234f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e75/4089602/8963b6a95fe0/kisup201234f2.jpg

相似文献

1
Chapter 2: Use of iron to treat anemia in CKD.第2章：铁剂在慢性肾脏病贫血治疗中的应用。
Kidney Int Suppl (2011). 2012 Aug;2(4):292-298. doi: 10.1038/kisup.2012.34.
2
Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015).美国非透析依赖型慢性肾脏病（CKD）患者贫血治疗的趋势（2006-2015 年）。
BMC Nephrol. 2018 Nov 9;19(1):318. doi: 10.1186/s12882-018-1119-7.
3
Oxidative stress in uremia: the role of anemia correction.尿毒症中的氧化应激：纠正贫血的作用。
J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S174-7. doi: 10.1681/ASN.2006080911.
4
[Clinical management of anemia in patients with CKD].[慢性肾脏病患者贫血的临床管理]
G Ital Nefrol. 2017 Mar;34(Suppl 69):20-35.
5
Iron Deficiency Anemia in Chronic Kidney Disease.慢性肾脏病中的缺铁性贫血。
Acta Haematol. 2019;142(1):44-50. doi: 10.1159/000496492. Epub 2019 Apr 10.
6
2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.2008年日本透析治疗学会：慢性肾脏病肾性贫血指南
Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.
7
Altered expression of intestinal duodenal cytochrome b and divalent metal transporter 1 might be associated with cardio-renal anemia syndrome.十二指肠细胞色素b和二价金属离子转运蛋白1在肠道中的表达改变可能与心肾贫血综合征有关。
Heart Vessels. 2017 Nov;32(11):1410-1414. doi: 10.1007/s00380-017-1013-4. Epub 2017 Jul 1.
8
Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats.枸橼酸铁作为磷酸盐结合剂，可减轻 5/6 肾切除 CKD 大鼠的贫血、肾功能障碍、氧化应激、炎症和纤维化。
J Pharmacol Exp Ther. 2018 Oct;367(1):129-137. doi: 10.1124/jpet.118.249961. Epub 2018 Aug 9.
9
Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.静脉补铁与口服补铁治疗 CKD 贫血的疗效比较：一项更新的系统评价和荟萃分析。
Am J Kidney Dis. 2016 Nov;68(5):677-690. doi: 10.1053/j.ajkd.2016.04.018. Epub 2016 Jun 16.
10

引用本文的文献

1
Safety of an Accelerated Ferric Gluconate Inpatient Infusion Regimen.葡萄糖酸铁加速住院输注方案的安全性。
J Pharm Technol. 2024 Oct 27:87551225241288144. doi: 10.1177/87551225241288144.
2
Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-dialysis Chronic Kidney Disease Patients: A Non-inferiority Study.口服脂质体铁剂与注射用蔗糖铁治疗非透析慢性肾脏病患者贫血的非劣效性研究
Cureus. 2024 Sep 24;16(9):e70114. doi: 10.7759/cureus.70114. eCollection 2024 Sep.
3
Care of Adults with Advanced Chronic Kidney Disease.

本文引用的文献

1
Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease.血清铁标志物不能充分指导慢性肾脏病的铁补充。
Clin J Am Soc Nephrol. 2011 Jan;6(1):77-83. doi: 10.2215/CJN.04190510. Epub 2010 Sep 28.
2
Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.铁调素不能作为维持性红细胞生成刺激剂治疗的血液透析患者铁需求的生物标志物。
Nephrol Dial Transplant. 2010 Dec;25(12):3996-4002. doi: 10.1093/ndt/gfq321. Epub 2010 Jun 10.
3
Iron homeostasis and the inflammatory response.
晚期慢性肾脏病成人患者的护理
J Clin Med. 2024 Jul 26;13(15):4378. doi: 10.3390/jcm13154378.
4
The Efficacy and Safety of Roxadustat for the Treatment of Posttransplantation Anemia: A Randomized Study.罗沙司他治疗移植后贫血的疗效和安全性：一项随机研究。
Kidney Int Rep. 2024 Apr 15;9(6):1705-1717. doi: 10.1016/j.ekir.2024.04.021. eCollection 2024 Jun.
5
Optimal Oral Iron Therapy for Iron Deficiency Anemia Among US Veterans.美国退伍军人缺铁性贫血的最佳口服铁治疗。
JAMA Netw Open. 2024 May 1;7(5):e2414305. doi: 10.1001/jamanetworkopen.2024.14305.
6
Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria.罗沙司他通过增加产生短链脂肪酸的肠道细菌来减轻接受促红细胞生成剂抵抗的维持性血液透析患者的炎症状态。
Eur J Med Res. 2023 Jul 10;28(1):230. doi: 10.1186/s40001-023-01179-3.
7
Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?治疗缺铁对合并肾功能不全的急性心力衰竭患者的益处更大吗？
Life (Basel). 2023 Mar 31;13(4):915. doi: 10.3390/life13040915.
8
A randomized trial of once daily versus twice daily dosing of oral iron in CKD.一项关于 CKD 患者口服铁剂每日一次与每日两次给药的随机试验。
Sci Rep. 2023 Jan 4;13(1):141. doi: 10.1038/s41598-022-26589-x.
9
Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD.罗沙司他治疗非透析和透析依赖性慢性肾脏病贫血患者的铁状态变化。
Kidney360. 2022 Jun 29;3(9):1511-1528. doi: 10.34067/KID.0001442022. eCollection 2022 Sep 29.
10
Reticulocyte and Erythrocyte Hemoglobin Parameters for Iron Deficiency and Anemia Diagnostics in Patient Blood Management. A Narrative Review.用于患者血液管理中铁缺乏和贫血诊断的网织红细胞及红细胞血红蛋白参数。一篇叙述性综述。
J Clin Med. 2021 Sep 19;10(18):4250. doi: 10.3390/jcm10184250.
铁平衡和炎症反应。
Annu Rev Nutr. 2010 Aug 21;30:105-22. doi: 10.1146/annurev.nutr.012809.104804.
4
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.美国食品药品监督管理局报告：静注用铁复合物用于治疗慢性肾脏病成人患者的缺铁症。
Am J Hematol. 2010 May;85(5):315-9. doi: 10.1002/ajh.21656.
5
Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?慢性肾脏病非透析贫血患者的铁治疗应答能否预测？
Clin J Am Soc Nephrol. 2010 Mar;5(3):409-16. doi: 10.2215/CJN.04280609. Epub 2009 Dec 17.
6
Ferric carboxymaltose in patients with heart failure and iron deficiency.缺铁性心力衰竭患者的羧基麦芽糖铁。
N Engl J Med. 2009 Dec 17;361(25):2436-48. doi: 10.1056/NEJMoa0908355. Epub 2009 Nov 17.
7
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).慢性肾脏病患者的贫血管理：欧洲肾脏最佳实践（ERBP）贫血工作组的立场声明
Nephrol Dial Transplant. 2009 Feb;24(2):348-54. doi: 10.1093/ndt/gfn653. Epub 2008 Nov 26.
8
Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation.血液透析患者血清铁蛋白升高与铁饱和度降低并存：炎症的作用
Clin J Am Soc Nephrol. 2008 Nov;3(6):1691-701. doi: 10.2215/CJN.01070308. Epub 2008 Oct 15.
9
Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis.静脉注射与口服铁剂补充治疗慢性肾脏病贫血的系统评价和荟萃分析。
Am J Kidney Dis. 2008 Nov;52(5):897-906. doi: 10.1053/j.ajkd.2008.05.033. Epub 2008 Oct 8.
10
Variability of ferritin measurements in chronic kidney disease; implications for iron management.慢性肾脏病中铁蛋白测量的变异性；对铁管理的影响。
Kidney Int. 2009 Jan;75(1):104-10. doi: 10.1038/ki.2008.526. Epub 2008 Oct 8.